Outpatient Bispecific Therapy May Be Feasible and Safe in Cancer

Commentary
Video

Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.

It may be feasible and safe to administer bispecific T-cell engager (BiTE) therapy to patients with cancer in an outpatient setting if the right infrastructure is put into place, according to Kathy Mooney, MSN, RN, ACNS-BC, BMTCN®, OCN®.

In a conversation with CancerNetwork® at the 2024 Oncology Nursing Society (ONS) Congress, Mooney, clinical program director at Johns Hopkins Hospital and Johns Hopkins Health System, spoke about the rationale for researching the use of BiTE therapy in an outpatient setting to ensure patient safety. Additionally, she highlighted the importance of collaboration among nurses, pharmacy providers, and social workers to monitor patients during the treatment process.

According to findings that Mooney presented at the meeting, of 19 patients who received teclistamab-cqyv (Tecvayli) in an outpatient setting since January 2023, 15 underwent admission within 30 days after beginning therapy. Additionally, 13 of these patients had cytokine release syndrome and/or immune effector cell-associated neurotoxicity syndrome requiring management, although there were no grade 3/4 toxicities.

Transcript:

We were looking to adopt an outpatient model for our patients [receiving] BiTE therapy. We have experience using outpatient therapy options for bone marrow transplant and CAR T cells, so we felt confident that we could treat our patients [receiving] BiTE in that same space using our same guiding principles. We wanted to make sure that it was safe for the patients, it was feasible, and that we could treat as many patients as possible in that space.

We started the process with a BiTE workgroup. We invited members in different areas of the team, including nursing and pharmacy providers. We had our social work colleagues come and join us. We tried to identify all areas where these patients would be interacting with our team members and make sure that they were included in the workgroup so that they could provide their insights to the process.

What I’d like people to know is that [BiTE therapy] is feasible in an outpatient setting if you have the right infrastructure in place. Thinking through the possibilities of the patients needing admission in a timely fashion and making sure that you have that setup within your program, you can definitely do this in the outpatient setting, and it can be safe for patients.

Reference

Mooney K, Allen N, Anderson K, Zukas A. Taking a BiTE out of hospital admission days using a team approach to managing patients at risk for treatment related toxicities. Presented at: 2024 Oncology Nursing Society Congress; April 24-28, 2024; Washington DC.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Related Content